Simposio de La Roche-Posay en el Congreso Mundial IMCAS 2024
Feb. 2024
LA ROCHE-POSAY EN IMCAS 2024
IMCAS 2024: Tratamiento práctico del melasma
Ya puedes ver al Dr. Hassan GALADARI en el Congreso Mundial IMCAS 2024 mientras habla de la gestión práctica de los pacientes con melasma, desde la patogénesis hasta las opciones de tratamiento.
Presented Posters
Discovery of 2-mercapto nicotinoyl glycine
A new potent skin lightening agent with a proven clinical efficacy
Melanin production inhibitors currently marketed tyrosinase, the rate limiting enzyme in melanin synthesis process. Yet only a few have demonstrated clinical efficacy while some present safety issues.
2-Mercaptonicotinoyl glycine: a new molecule that prevents and decreases uv-induced pigmentation.
Hyperpigmentation disorders are a frequent reason for dermatology consultations as they can impair quality of life.
A topical formula containing proxylane and niacinamide augments the anti-ageing benefits of a non-ablative laser treatment
Minimally invasive aesthetic procedures, such as microneedling and non-ablative laser treatment, are rapidly increasing in popularity due to minimal recovery and downtime with effective results for skin rejuvenation.
Pigmentary disorders, prevalence, impact on quality of life, social stigmatization: Results of the first large international survey
Pigmentary disorders (PD) such as Melasma, Post-inflammatory Hyperpigmentation (PIH), Solar Lentigo, Peri-Orbital Hyperpigmentation (POH) and Axillary Hyperpigmentation (AH) are frequent dermatological conditions, but little is known on their real-world prevalence and impact.